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Native mass spectrometry combined with
enzymatic dissection unravels glycoform
heterogeneity of biopharmaceuticals
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Eugen Damoc5, Johann Holzmann2,4 & Christian G. Huber 1,2
Robust manufacturing processes resulting in consistent glycosylation are critical for the
efﬁcacy and safety of biopharmaceuticals. Information on glycosylation can be obtained by
conventional bottom–up methods but is often limited to the glycan or glycopeptide level.
Here, we apply high-resolution native mass spectrometry (MS) for the characterization of the
therapeutic fusion protein Etanercept to unravel glycoform heterogeneity in conditions of
hitherto unmatched mass spectral complexity. Higher spatial resolution at lower charge
states, an inherent characteristic of native MS, represents a key component for the successful
revelation of glycan heterogeneity. Combined with enzymatic dissection using a set of pro-
teases and glycosidases, assignment of speciﬁc glycoforms is achieved by transferring
information from subunit to whole protein level. The application of native mass spectrometric
analysis of intact Etanercept as a ﬁngerprinting tool for the assessment of batch-to-batch
variability is exempliﬁed and may be extended to demonstrate comparability after changes in
the biologic manufacturing process.
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The approval of biopharmaceuticals requires in-depthcharacterization at the molecular level involving con-ﬁrmation of the amino-acid sequence as well as compre-
hensive assessment of post-translational modiﬁcations (PTMs)1.
Consistent glycosylation constitutes an important quality attri-
bute as it may impact the efﬁcacy and safety of the therapeutic
product. Current analytical methods comprise the characteriza-
tion of released glycans or of glycopeptides, providing detailed
information on the average molecular composition2,3. Alter-
natively, the existence and relative abundance of speciﬁc pro-
teoforms can be revealed by the determination of intact protein
masses4, as has been accomplished for several therapeutic
monoclonal antibodies (mAbs)5–9. Conventional mass determi-
nation under denaturing conditions is restricted to samples of
limited complexity due to the overlap of broad signal clusters
observed for the respective charge states. In contrast, under the
conditions applied in native mass spectrometry (MS), protein
folding is preserved resulting in lower charge states situated at
higher m/z in the corresponding mass spectrum. The inherently
higher spatial resolution at high m/z allows separation and thus
deconvolution of these broad signal clusters. This technique is
well established for the characterization of non-covalent protein
complexes, e.g., large protein assemblies10–13 or antibody–drug
conjugates14,15. Native MS has also been applied for qualitative
and semi-quantitative analysis of composite mixtures of
mAbs16,17 as well as for characterization of micro-heterogeneity
in therapeutic proteins arising from, for example, N-glycosylation
variants18–22. In this context, the glycan heterogeneity of human
erythropoietin (26–30 kDa) and human plasma properdin (54
kDa) was successfully revealed upon integration of intact protein
mass determination by native MS, middle–down analysis of
proteolytic glycopeptides, and enzymatic deglycosylation, which
facilitated the assignment of PTM compositions to the detected
intact protein masses22.
Etanercept, the active pharmaceutical ingredient of Enbrel®, is
a highly glycosylated therapeutic Fc-fusion protein. This bio-
pharmaceutical acts as an inhibitor for tumor necrosis factor
(TNF), an important mediator protein of inﬂammatory cell
responses, and has been licensed for the treatment of auto-
immune disorders such as rheumatoid and psoriatic arthritis23.
Etanercept consists of a TNF-α receptor (TNFR) domain fused to
the Fc portion of human IgG1 and forms dimers stabilized by three
intermolecular disulﬁde bonds resulting in a theoretical protein
mass of 102.4 kDa (Fig. 1a; for amino-acid sequence see Supple-
mentary Fig. 1)24. The resultant protein comprises multiple glyco-
sylation sites: four N- and 26 O-glycosylation sites in the dimeric
TNFR domain, as well as two N-glycan sites in the Fc domain, as
previously characterized via released N- and O-glycan analysis by
hydrophilic interaction liquid chromatography with ﬂuorescence
detection24. In the same study, O-glycopeptides were analyzed by
HPLC-MS with collision-induced- and electron transfer dissocia-
tion. The O-glycans were found to be predominantly of the core
1 subtype (Galβ1-3GalNAc-) substituted by up to two sialic acid
residues (N-acetylneuraminic acid, Neu5Ac)24.
Here, we report on the applicability of native MS for resolution of
the highly complex glycosylation pattern of the 130 kDa therapeutic
Fc-fusion protein Etanercept. Extending previous work on smaller
proteins22 we take advantage of the superior spatial resolution for
protein isoforms at lower charge states detectable under native
conditions in order to uncover glycoforms and explore the limits of
mass spectral resolution and mass accuracy with glycoproteins
larger than 100 kDa. To reduce spectral complexity and hence
facilitate the annotation of glycoforms and other proteoforms, we
employ enzymatic dissection using speciﬁc proteases and glycosi-
dases. Our approach serves to provide comprehensive information
on both the N- and O-glycosylation patterns at different levels of
molecular complexity. We also demonstrate that molecular infor-
mation gained at lower structural levels (i.e., glycopeptides, protein
subunits) can successfully be integrated to facilitate glycoform
annotation at higher structural levels (i.e., whole protein upon
partial deglycosylation) through the application of advanced com-
putational tools. Thus, the obtained molecular mass information at
the whole protein level allows us to propose of the most likely
combination of glycan structures. Finally, native MS of Etanercept
may serve as a rapid ﬁngerprinting tool for the assessment of batch-
to-batch variability at the intact protein level.
Results
Native mass spectrometry of Etanercept at the intact level. First,
we assessed the feasibility of intact mass measurements of
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Fig. 1 Molecular structure and native mass spectrometry of Etanercept. a Schematic illustration of dimeric Etanercept consisting of a TNFR and an Fc
domain. Disulﬁde bonds in the Fc region are indicated as yellow lines; disulﬁde bridges in the TNFR domain are not shown. Monosaccharide symbols are
listed. Exemplary cleavage sites of IdeS, PNGase F and sialidase are indicated. Native mass spectra of b intact Etanercept (Rset= 17,500 at m/z 200),
d Etanercept digested with sialidase or f PNGase F (Rset= 35,000 at m/z 200), and h a combination of PNGase F/sialidase, respectively (Rset= 70,000 at
m/z 200). Charge states are indicated. Zooms into the most abundant charge states are shown in c, e, g, and i
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Etanercept on a Thermo ScientiﬁcTM ExactiveTM Plus EMR mass
spectrometer. Distinctive features of this instrument include (i)
an extended mass range of m/z 350-20,000 and (ii) the option of
trapping ions in the higher energy collisional dissociation (HCD)
cell at adjustable gas pressure. For the analysis, Enbrel® drug
product was extensively buffer exchanged to ammonium acetate
and directly infused by static nano-ESI. We observed a charge
state distribution from m/z 4800 to 6500 corresponding to
charges of 26+ to 20+ on the intact molecule (Fig. 1b). Each
charge state consisted of numerous signals, potentially arising
from different proteoforms including glycan variants, as illu-
strated in the zoom of charge state 24+ (Fig. 1c). The superior
spatial resolution of native MS was a prerequisite to this analysis,
as the charge states typically obtained for such complex proteins
under denaturing conditions (50+ to 35+) would overlap
(simulation shown in Supplementary Fig. 2).
Deconvolution of the raw spectrum of intact Etanercept
using the ReSpectTM algorithm (embedded in the Thermo
ScientiﬁcTM BioPharma FinderTM software) resulted in masses
ranging from 125 to 131 kDa for the intact protein variants (see
Supplementary Fig. 3). The multitude of signals and their relative
abundances observed in the raw data obtained with an
instrument resolution setting (abbreviated as Rset in the
following) of 17,500 at m/z 200 (see Fig. 1c and Supplementary
Fig. 3a) is clearly reﬂected in at least 70 distinguishable protein
signals in the deconvoluted spectrum (Supplementary Fig. 3b).
Taking into account a theoretical average mass of 102,160 Da for
the total Etanercept amino-acid sequence (dimer without
C-terminal lysine residues, 29 disulﬁde bonds25), the experimen-
tally determined masses evidence residual masses of ~ 23,000 to
29,000 Da, corresponding to the glycan portion of the protein.
By virtue of the vast number of glycan combinations possible
from structures reported for Etanercept to date24, the intact
Etanercept spectra were too complex to assign speciﬁc glycoforms
to the residual masses. Subsequently, a systematic strategy
applying glycosidases and/or proteases was employed to succes-
sively decrease the complexity and molecular size of the sample.
Ultimately, this strategy aimed at assembling all modiﬁcations
present in Etanercept, as determined at different structural levels.
Thus, we performed (i) de-sialylation with sialidase, (ii) de-N-
glycosylation with PNGase F, (iii) a combination of both, (iv)
double digestion with sialidase and O-glycosidase, (v) decom-
position of Etanercept into TNFR and Fc domain by IdeS
digestion, and (vi) digestion into glycopeptides using trypsin or
AspN, followed by mass spectrometric analysis of the obtained
products.
Determination of O-glycoforms upon removal of N-glycans.
Taking advantage of the substrate speciﬁcity of different
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Fig. 2 Annotation of Etanercept O-glycoforms. a Deconvoluted spectrum of Etanercept after digestion with PNGase F/sialidase (raw spectrum shown in
Fig. 1h). O-glycoforms, i.e., the number of core 1 units (Hex-HexNAc), as well as lysine variants are annotated. Each symbol indicates a certain number of O-
glycan cores. b Deconvoluted spectrum of Etanercept after digestion with PNGase F (raw spectrum shown in Fig. 1f). The number of O-glycan cores is
indicated by a speciﬁc symbol in accordance with Fig. 2a. Multiple signals annotated with the same symbol represent sialic acid (Neu5Ac) variants of each
O-glycoform. The number of Neu5Ac residues is indicated above each annotated peak. Peak lists with all possible glycoform assignments are available in
Supplementary Data 1
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glycosidases, we removed the N-glycans using PNGase F, sialic
acids using sialidase, or both in a combined enzymatic digest
(see Fig. 1a; resulting schematic protein structures are shown in
Supplementary Fig. 4). Mass spectrometric analysis expectedly
showed a shift of signals toward lower m/z, as well as reduced
complexity, after glycosidase digestion (Fig. 1d–i). Removal of
both the N-glycans and sialic acid residues resulted in glyco-
forms which differed only by the number of O-glycan cores
(Fig. 1h, i; Supplementary Fig. 4). Consequently, the most
abundant peaks in the deconvoluted spectrum of the double
glycosidase digest differed by a mass of 365.1 Da, attributable to
a hexose (Hex) and an N-acetylhexosamine (HexNAc) residue,
characteristic of a core 1 O-glycan structure (Fig. 2a). Con-
sidering multiples of core 1 O-glycan masses, we were able to
assign the speciﬁc O-glycosylation variants substituted with
14–23 core 1 units as shown in Fig. 2a, using a custom software
tool (MoFi)26. For each O-glycoform, variants with one or two
lysine residues as well as an additional hexose or HexNAc
residue were detected. Presence of lysine variants is common in
Fc domain containing proteins and results from incomplete
clipping of C-terminal lysine residues from the heavy chain by
carboxypeptidase B in mammalian protein expression sys-
tems27. Owing to the lower complexity, and consequent lower
number of signals per charge state, mass spectrometric analysis
of the above described double digest could also be performed
under denaturing conditions (Supplementary Fig. 5). Indeed,
the masses and relative abundances determined under native
and denaturing conditions were highly consistent in both mass
spectrometric approaches (Supplementary Fig. 5e).
Compared with the PNGase F/sialidase double digest, the
spectrum of PNGase F treated Etanercept displays a higher
complexity, arising from the sialic acid variants of O-glycoforms
(Fig. 1f, g; Supplementary Fig. 4), visible as a series of signals
differing in molecular mass by 291.3 Da for a given number of
attached O-glycan cores (Fig. 2b). In a purely mass-based
approach, i.e., if relative abundances from the spectrum shown
in Fig. 2a were not taken into account, two possible glycoforms
could be assigned for each peak in the deconvoluted spectrum
within the accepted mass tolerance of ±5 Da. Considering the
relative abundances of O-glycoforms as observed in the double
glycosidase digest (Fig. 2a), sialylated variants of the correspond-
ing O-glycoforms can be annotated (Fig. 2b). Thus, the most
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Fig. 3 N-glycosylation of Etanercept TNFR and Fc domains. a Deconvoluted spectrum of dimeric TNFR digested with sialidase and O-glycosidase acquired
under native conditions (raw spectrum shown in Supplementary Fig. 6c, d). The most probable glycan structures lacking sialic acids are annotated. b
Deconvoluted spectrum of Fc dimer upon native MS (raw spectrum shown in Supplementary Fig. 7). The most probable N-glycoforms and C-terminal
lysine variants are annotated. Asterisks indicate Na+ adducts. Peak lists with all possible glycoform assignments are available in Supplementary Data 1
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abundant sialylation variants arise from O-glycoforms substituted
with 18–21 core 1 O-glycan units (yellow squares, blue
triangles, red circles, and dark green triangles in Fig. 2b).
However, this abundance-based approach remains insufﬁcient
for unambiguous annotation of a series of sialylation variants
observed between 113,500 and 115,500 Da; the respective series
may be explained by both 17 and 21 O-core variants substituted
with different numbers of sialic acids. As both the 17 and 21 O-
glycoforms are of similar abundance in the double glycosidase
digest (light green stars: 31.7% and dark green triangles: 33.7%;
Fig. 2a), discrimination between these two alternatives is not
possible. Given that the most abundant sialylated variants of
each O-glycoform in the PNGase F digest consistently display
between 1.2 and 1.3 as a characteristic ratio of Neu5Ac residues
to O-glycan cores, a unique annotation for this series can be
attributed to 17 O-glycan cores (light green stars in Fig. 2b).
Furthermore, series of smaller signals shifted by ~128 Da
present in the deconvoluted spectrum of PNGase F digested
Etanercept most probably signify the C-terminal lysine variants.
The 21 Neu5Ac variant of the glycoform series substituted with
20 core 1 O-glycans (red circles, Fig. 2b) is not annotated owing
to a mass deviation outside of the accepted mass tolerance
window (±5 Da), most likely owing to interference with another
proteoform.
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Fig. 4 N- and O-glycosylation of Etanercept lacking sialic acids. a Deconvoluted spectrum of Etanercept treated with sialidase and O-glycosidase acquired
under native conditions (raw spectrum is shown in Supplementary Fig. 8b). The most probable glycan structures lacking sialic acids are annotated. The six
most abundant N-glycoforms are boxed and marked as A to F, respectively. b Deconvoluted spectrum of sialidase-treated Etanercept upon native MS (raw
spectrum is shown in Fig. 1d). The most probable glycoforms are annotated. N-glycan structures are referred to as A to F as speciﬁed in Fig. 4a; O-
glycoforms are labeled according to Fig. 2a. Peak lists with all possible glycoform assignments are available in Supplementary Data 1
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Assessment of N-glycosylation of the TNFR domain. Although
the spectrum of sialidase-treated Etanercept is less complex com-
pared with the PNGase F digestion (Fig. 1d, e), attempts to assign N-
glycoforms in an analogous strategy to that applied for O-glyco-
forms at the whole protein level failed. This is mainly due the
diversity of possible N-glycan structures and the large residual mass
arising from six N-glycans present on the whole protein. Taking into
account the O-glycoforms identiﬁed in the combined PNGase F/
sialidase digest (Fig. 2a), several possible compositions of the six
desialylated N-glycans remained for each residual mass at this stage.
Therefore, we pursued enzymatic dissection of Etanercept employ-
ing the IdeS protease to cleave the protein in the hinge region and
subsequently separate the TNFR and Fc domains by afﬁnity pur-
iﬁcation (Supplementary Fig. 4). This middle-up approach allowed
for isolated analysis of the two domains, thereby considerably
reducing the number of possible N-glycoform assignments.
In order to obtain information on N-glycan variants of TNFR, we
ﬁrst removed the O-glycans using O-glycosidase. As the employed
enzyme is only active on unsubstituted O-glycan cores, the digest
was performed in combination with sialidase (Supplementary
Fig. 4). Therefore, the resulting peaks comprised only N-glycan
variants lacking in sialic acid (Fig. 3a and Supplementary Fig. 6).
The most abundant mass of 62,139Da can be attributed to dimeric
TNFR plus four N-glycan cores and additionally 10 hexose-, 10
HexNAc-, and two fucose-residues. As several structural isomers of
this monosaccharide composition exist, unambiguous assignment
of N-glycan structures is still not possible at this level.
To pinpoint the exact N-glycan structures present on the TNFR
domain, we generated a site-speciﬁc library of N-glycans based on
glycopeptides obtained after AspN digestion in a bottom–up
glycopeptide analysis. Considering the site-speciﬁc fractional
abundances of the identiﬁed glycopeptides (taking into account
removal of sialic acids, see Supplementary Table 1), the most
abundant glycoform (62,139 Da) most likely carries two A2G2
(68% fractional abundance at N149) and two A2G2F (83%
fractional abundance at N171) N-glycans (for structures, see
Supplementary Table 2). This N-glycan composition corresponds
to four N-glycan cores and eight hexose-, eight HexNAc-, and
two fucose-residues, which leads us to conclude that the two
remaining hexose- and HexNAc-residues, respectively, must be
attributed to two O-glycan cores which were not removed by the
O-glycosidase. In the same manner, most of the peaks present in
the spectrum could unambiguously be ascribed to speciﬁc N-
glycan combinations, i.e., N-glycoforms based on the fractional
abundances obtained from glycopeptide data. In addition to the
species comprising two residual O-glycan cores, variants bearing
none or up to three O-glycan cores were detectable (Fig. 3a).
Determination of N-glycosylation of the Fc domain. Native MS
of the afﬁnity-puriﬁed Fc domain yielded molecular masses for the
dimeric Fc domain (Fig. 3b and Supplementary Fig. 7), although no
intermolecular disulﬁde bonds are present (Supplementary Fig. 4).
Taking advantage of the corresponding tryptic glycopeptide abun-
dances (N317, Supplementary Table 1) the most prominent gly-
coforms were assigned to A2G0F/A2G0F (50,464.7 Da), A2G0F/
A2G1F (50,626.7 Da) and the isobaric variants A2G1F/A2G1F or
A2G0F/A2G2F (50,788.7 Da) (Fig. 3b). Based on hit scores pro-
vided by MoFi, the abundance of the isobaric variants can be
estimated at 70% for N-glycoform A2G1F/A2G1F and 30% for
A2G0F/A2G2F. In addition, we observed C-terminal lysine variants
at a relative abundance of ∼24.3% (+Lys) and 2.8% (+2 Lys). This
is in good agreement with the bottom–up data for the C-terminal
tryptic peptides SLSLSPG (88.1%) and SLSLSPGK (11.9%), which
corresponds to 0.881 × 0.119 × 2= 21.0% (+Lys) and 0.119²=
1.4% (+2 Lys) variant in the Fc dimer.
Integrating glycosylation data on the whole protein level.
Taking into account the N-glycan combinations identiﬁed on the
subunit level (Fig. 3a, b), N-glycoforms lacking sialic acid can be
assigned in sialidase/O-glycosidase treated Etanercept (Fig. 4a,
Supplementary Fig. 4). Thus, the most abundant variant observed in
Fig. 4a (112,732Da) results from a combination of the most
abundant TNFR N-glycoform (62,139 Da, Fig. 3a) and the second-
most abundant Fc glycoform (50,627 Da, Fig. 3b) minus two water
molecules incorporated upon proteolysis. In the same manner,
other glycoforms of sialidase/O-glycosidase treated Etanercept can
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Fig. 5 Comparison of pre- and post-change batches of Enbrel® upon native mass spectrometry at the intact protein level. a Mirror plot of deconvoluted
mass spectra of Enbrel® EU pre- and post-change batch 1. b Mirror plot of deconvoluted mass spectra of Enbrel® EU post-change batches 1 and 2. Spectra
were acquired at Rset= 35,000 at m/z 200. Mass spectra were acquired with identical instrument settings (SID 100 eV; CE 25 eV)
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be assigned upon integration of data on N-glycans for TNFR- and
Fc domains, i.e., merging the assignments presented in Fig. 3a and
3b: six different N-glycan combinations substituted with up to three
residual O-glycan cores could be identiﬁed (Fig. 4a). This annota-
tion is consistent with the assignment of glycoforms based on a site-
speciﬁc N-glycopeptide library (Supplementary Table 1), verifying
coherence of data integration at different digestion levels.
Moving up one structural level, we attempted to assign N- and
O-glycoforms after removal of sialic acid residues using the same
approach. Upon integration of the most abundant N-glycan
combinations annotated in the sialidase/O-glycosidase digest of
Etanercept (Fig. 4a) and the O-glycoforms detected in the
PNGase F/sialidase digest (Fig. 2a), it is possible to assign
desialylated N- and O-glycans at the whole protein level (Fig. 4b).
Annotation of Etanercept lacking sialic acid conﬁrms that the two
TNFR N-glycosylation sites are mainly occupied by 2 × A2G2 and
2 × A2G2F glycans, whereas the Fc N-glycosylation sites
predominantly carry two different N-glycan structures, namely
A2G0F and A2G1F. In addition, the prevalent O-glycoforms
comprise 18, 19, and 20 O-glycan cores, respectively.
As far as glycosylation of intact (untreated) Etanercept is
concerned, comparison of the spectra depicted in Fig. 1b and 1d
clearly demonstrates the augmented complexity upon incorpora-
tion of sialic acid. Assignment of speciﬁc glycoforms on the whole
protein level was generally ambiguous owing to insufﬁcient
resolution of multiple glycovariants, which differ only slightly in
mass. Nevertheless, spectra of intact Etanercept displayed highly
distinctive peak patterns, which prompted evaluation of the
developed native MS method for assessment of glycan consistency
in different Enbrel® production batches.
Comparison of Enbrel® batches by native MS. The analysis of
intact Etanercept by native MS, as shown in Fig. 5, unravels between
92 and 122 distinct signals, providing a detailed and characteristic
ﬁngerprint of product heterogeneity. A change in the quality proﬁle
of Enbrel® production batches has previously been reported and was
attributed to a decrease in A2G2F N-glycan structures as well as an
increase in C-terminal lysine variants in post- compared with pre-
change batches28. Intriguingly, we also observed differences in intact
masses for pre- and post-change material (Fig. 5a), whereas spectra
of two post-change batches were highly comparable (Fig. 5b). The
observed differences could majorly be assigned to the N-glycan level,
as native spectra of Enbrel® batches were more comparable after
removal of N-glycans by PNGase F (Supplementary Fig. 9), con-
sistent with previously published N-glycosylation differences28.
Discussion
Mass spectrometric analysis of intact proteins under native-like
conditions is a powerful tool to reveal coexisting glycoforms and
may be supported by integration of middle–down and bottom–up
proteomics data22. In contrast to released glycan or glycopeptide
analysis, which yields information on an average glycoform, the
context of glycosylation is conserved at the intact protein level,
providing valuable information on true glycoform heterogeneity.
Pursuing the systematic characterization of Etanercept, a highly
glycosylated biopharmaceutical of 128 kDa mass, we have taken
the concept of integrative mass spectrometric analysis to a new
level of complexity. Our study reveals the coexistence of >100
glycoforms in a highly deﬁned drug product. From a technical
standpoint, the higher spatial resolution achieved upon mass
spectrometric analysis of Etanercept in its native, folded state, is
mandatory for the separation of the broad signal clusters arising
from >100 proteoforms which differ in mass by as little as 20–40
Da (depending on molecular mass).
In excess of revealing unprecedented glycoform heterogeneity
for a protein larger than 100 kDa, we aimed to assign speciﬁc
glycovariants for the determined masses. Annotation of glyco-
forms to masses obtained for intact Etanercept using basic
combinatorial approaches results in a vast number of ambiguous
assignments: assuming a total of six N- and 24 O-glycans as well
as 11 different N-glycan and three different O-glycan structures24
for the most abundant proteoform of Etanercept (128,489 Da,
Supplementary Fig. 3b), we obtain a total of 500 quadrillions
(116 × 324 ≈ 5.00 × 1017) potential glycan combinations to match
the residual mass (128,489 – 102,160= 26,329 Da). Additional
constraints must be introduced in order to achieve unambiguous
peak assignments. We therefore established an enzymatic dis-
section procedure beneﬁcial in both reducing sample complexity
as well as the residual mass to be explained.
Information on the number of O-glycan cores and their substitu-
tion by sialic acid could be deduced upon glycosidase digestion of
intact Etanercept (Fig. 2). The extended search space arising from the
structural diversity of N-glycans prompted us to integrate information
on the glycan structures and abundances derived from glycopeptide
data. Isolated analysis of afﬁnity-puriﬁed Fc and TNFR revealed that
core-fucosylated N-glycans lacking galactose predominate on the Fc
domain, whereas on TNFR most N-glycans are galactosylated and
structures lacking core fucose occur (Fig. 3). Using MoFi, systematic
integration of data obtained forO-glycoforms,N-glycopeptides as well
as N-glycoforms of TNFR and Fc domains, enabled annotation of
masses up to the level of desialylated Etanercept. Supplementary Fig. 4
provides a roadmap for the transfer of information obtained from
different digestion levels. Our strategy pursuing annotation of speciﬁc
glycan structures on the whole protein level upon signiﬁcant reduc-
tion of search space thus extends the previously described concept of
assigning glycan compositions alone22. Finally, investigation at dif-
ferent structural levels enables localization of qualitative differences,
exempliﬁed by the higher comparability of Enbrel® batches upon
removal of N-glycans as compared to the intact protein level, indi-
cating that the observed differences mainly arise from N-glycosylation
(Fig. 5, Supplementary Fig. 9).
Our study not only introduces a systematic strategy for gly-
coform assignment, but also assesses the current possibilities and
limitations of native MS. Attempts to annotate glycan patterns at
the level of intact Etanercept, including sialic acids, revealed that
consolidation of glycoforms generated too many combinations
for distinction by native MS, owing to overlapping isobaric var-
iants or glycoforms of very small mass differences (for instance,
two fucose- and one sialic acid-residue differ by only 1.0 Da; the
mass difference between four O-glycan cores and ﬁve sialic acids
is 5.0 Da). Thus, mass differences between intact and desialylated
Etanercept cannot simply be explained by multiples of sialic acid
masses, mainly because a signal observed in the spectrum of
intact Etanercept does not generally represent a single, distinct
glycoform. Intrinsic limitations of intact mass determination of
large proteins include (i) the presence of unresolvable adduct-
bound protein ions, (ii) overlapping signals of variants of small
mass difference, which cannot be adequately resolved by MS (iii)
the natural width of isotopic patterns of proteins containing
>10,000 atoms29. As a consequence of the latter point, it is
intrinsically impossible to resolve certain glycoforms as exem-
pliﬁed for an Etanercept PNGase F digest (Supplementary
Fig. 10), even at isotopic resolution29. This limitation can be
compensated, to some extent, through the integration of infor-
mation obtained at different structural levels, e.g., taking into
account relative abundances of the underlying O-glycoforms
observed in the absence of sialic acid (Fig. 2a). The coherence in
annotations clearly corroborates the feasibility of transferring
glycoform information from the subunit level to the larger con-
text of the whole protein.
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In conclusion, the analysis of glycoforms by native MS combined
with enzymatic dissection opens up new avenues in the char-
acterization of heavily glycosylated biopharmaceuticals. Compre-
hensive information on glycoform heterogeneity, fast analysis with
minimal sample preparation and product-characteristic ﬁngerprints
render our method highly attractive for the quality control of bio-
logics as well as for comparability studies following changes in the
manufacturing process. Assessment of biosimilarity and relative
quantiﬁcation of glycoforms at different levels of complexity will be
further explored in the future.
Methods
Materials. Cesium iodide (CsI) (Fisher Scientiﬁc, AC19282-010) was prepared at
2.0 mg mL−1 in 30% acetonitrile (Fisher, Optima® LC-MS grade), 30% methanol
(Fisher, Optima® LC-MS grade), and 40% water. Enbrel® (Amgen/Pﬁzer formerly
distributed by Immunex/Wyeth) was purchased from the pharmacy, and stored
and handled until analysis according to the manufacturer's instructions. Lot
numbers and expiry dates are listed in Supplementary Table 3.
Enzymatic digests and sample preparation. Enbrel®, supplied in formulation
buffer, was buffer exchanged into 100 mmol L−1 aqueous ammonium acetate (p.a.,
Merck, Darmstadt, Germany) using Micro Bio-Spin P-6 columns (Bio-Rad,
Vienna, Austria) with an exclusion cutoff of 6000 Da before MS analysis.
N-glycans were released from intact Etanercept using PNGase F from
Flavobacterium meningosepticum (Roche Applied Science, Mannheim, Germany).
For this purpose, 200 μg of the drug product were digested with 3.2 U of PNGase F
(enzyme-to-substrate ratio 16 U mg−1) in 15 mmol L−1 Tris/HCl (Sigma Life
Sciences, St. Louis, USA), pH 7.0, in a ﬁnal volume of 100 μL. The sample was
incubated for 17 h at 37 °C while shaking and then buffer exchanged into 100
mmol L−1 aqueous ammonium acetate using a Micro Bio-Spin P-30 column (Bio-
Rad) with an exclusion limit of 40,000 Da.
Intact Etanercept was desialylated using neuraminidase (sialidase) from
Arthrobacter ureafaciens (Roche Applied Science). Two hundred micrograms of
drug product were digested with 17 mU of sialidase (enzyme-to-substrate ratio 85
mU mg−1) in 40 mmol L−1 sodium acetate (puriss. p.a., Fluka Analytical,
Steinheim, Germany) pH 5.0, in a ﬁnal volume of 100 μL. The sample was
incubated for 17 h at 37 °C while shaking and then buffer exchanged into 100
mmol L−1 aqueous ammonium acetate using a Micro Bio-Spin P-30 column.
For release of N-glycans and sialic acids, 200 μg of drug product were digested
with 3.2 U of PNGase F and 17 mU of sialidase in 15 mmol L−1 Tris/HCl, pH 7.0,
in a ﬁnal volume of 100 μL. The sample was incubated for 17 h at 37 °C while
shaking and then buffer exchanged into 100 mmol L−1 aqueous ammonium acetate
using a Micro Bio-Spin P-30 column.
IdeS digestion and afﬁnity puriﬁcation of the Fc domain were performed using
the FragITTM kit (Genovis, Lund, Sweden), containing FragITTM and
CaptureSelectTM spin columns, according to manufacturer’s instructions. In brief,
400 μg of drug product was digested with immobilized FabRICATOR in a ﬁnal
volume of 100 μL of 20 mmol L−1 ammonium bicarbonate (≥ 99.0%, Sigma Life
Sciences). After 1.0 h incubation at 25 °C the sample was eluted and the column
was ﬂushed with 100 μL of 20 mmol L−1 ammonium bicarbonate to achieve
maximum recovery. The pooled eluates were loaded on a CaptureSelectTM column
containing an Fc afﬁnity matrix in order to separate the Fc and the TNFR domain.
The ﬂow-through of the puriﬁcation step contained the TNFR domain whereas the
Fc domain was eluted from the afﬁnity matrix with 100 mmol L−1 glycine (≥ 99%,
Sigma Life Sciences), pH 3.0. The eluate was neutralized immediately with
ammonium bicarbonate (1 mol L−1). Twenty mmol L−1 ammonium bicarbonate
was used as cleavage and binding buffer.
For native MS of TNFR and Fc, 75 μL of the CaptureSelectTM ﬂow-through or
the eluate, respectively, were buffer exchanged with 100 mmol L−1 aqueous
ammonium acetate using a Micro Bio-Spin P-6 column. N-glycans were released
from TNFR by addition of 750 U of PNGase F (New England BioLabs, Frankfurt
am Main, Germany) to 13 μL of the CaptureSelectTM ﬂow-through in a ﬁnal
volume of 25 μL of 20 mmol L−1 ammonium bicarbonate. The sample was
incubated for 17 h at 37 °C while shaking and then buffer exchanged into 100
mmol L−1 aqueous ammonium acetate using a Micro Bio-Spin P-30 column. For
release of sialic acids and O-glycans, TNFR was treated with a combination of
sialidase from A. ureafaciens and O-glycosidase from Enterococcus faecalis (New
England BioLabs). For this purpose, 1.0 μL of sialidase and 5.0 μL of O-glycosidase
solution were added to 20 μL of CaptureSelectTM ﬂow-through. After incubation for
17 h at 37 °C while shaking, the sample was buffer exchanged into 100mmol L−1
aqueous ammonium acetate using a Micro Bio-Spin P-30 column.
For glycopeptide analysis, Etanercept was reduced with 10 mmol L−1
dithiothreitol (G-Biosciences, St. Louis, USA) in 6 mol L−1 Gdn HCl (Sigma Life
Sciences), 50 mmol L−1 Tris/HCl (Sigma Life Sciences), 5.0 mmol L−1 EDTA, pH 8
(Sigma Life Sciences) for 1.0 h at 37 °C, and alkylated with 20 mmol L−1
iodoacetamide solution (G-Biosciences) for 1.0 h at 25 °C in the dark.
Subsequently, the buffer was exchanged to 50 mmol L−1 Tris/HCl, pH 8.0, using
Amicon Ultra 0.5 mL centrifugal ﬁlters with an exclusion cutoff of 10 kDa
(Millipore, Darmstadt, Germany). For proteolytic digestion, 8.0 μg of Trypsin
(Promega, Madison, USA) was added to 200 μg of Etanercept, and 1.0 μg of AspN
(sequencing grade, Roche Applied Science) was added to 50 μg of Etanercept,
respectively, followed by incubation for 17 h at 37 °C. Digestion was quenched by
addition of TFA (LC-MS grade, Fluka Analytical).
Native and denaturing mass spectrometry. All protein solutions were analyzed
at a concentration between 4 and 16 μmol L−1 (assuming an average molecular
mass of 128 kDa of intact Etanercept) in 100 mmol L−1 aqueous ammonium
acetate. Experiments were carried out on a Thermo ScientiﬁcTM ExactiveTM Plus
EMR mass spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany) equipped
with a Thermo ScientiﬁcTM Nanospray FlexTM ion source. Samples were directly
infused using conductive capillaries for static nanospray (catNo. ES387, Thermo
ScientiﬁcTM, San Jose, CA, USA) at a spray voltage of 1.2–1.6 kV. Ions were
accumulated in the HCD cell in order to allow efﬁcient trapping and desolvation.
Trapping gas pressure and voltage offset on the transport multipoles and ion lenses
were manually tuned. The scan range was set to m/z 1000–10,000. S-lens RF level
was set to 200. Instrument resolution, source induced dissociation, and collision
energy were optimized for each sample in order to achieve best signal-to-noise
ratios at highest possible resolution settings (typically between 17,500 and 70,000 at
m/z 200; higher resolution settings generally yielded noisier spectra of lower overall
signal intensity). Comparison of different Enbrel® batches was performed at
identical parameter settings. Spectra were acquired using rolling averaging in order
to increase the signal-to-noise ratios. Depending on sample complexity, between
5000 and 15,000 microscans were averaged. The instrument was mass-calibrated
based on signals detected from m/z 392.7 to m/z 11,304.7 using a solution of CsI.
Mass spectrometric data processing and peak assignment. Data were acquired
using XcaliburTM 3.0 software (Thermo Fisher Scientiﬁc) and raw spectra were
deconvoluted to zero-charge using the ReSpectTM algorithm in the BioPharma Fin-
derTM 1.0 SP1 software (Thermo Fisher Scientiﬁc). Deconvolution parameters were
adjusted for each spectrum and the deconvoluted spectrum was veriﬁed by manual
comparison with the raw data. Deconvoluted spectra were annotated by a compu-
tational tool, MoFi26, which employs a two-stage search algorithm. In brief, the ﬁrst
search stage assigns monosaccharide/PTM compositions to each peak. Optionally, the
software then compiles a hierarchical list of glycan combinations compatible with
these compositions. The latter step requires a glycan library as derived from glyco-
peptide or released glycan analysis. A deviation of up to ±5Da between experimental
and theoretical average masses was accepted. MoFi also calculates a score for each
assigned glycan combination by (1) multiplying the relative abundances of the
included glycans and (2), for each peak, scaling the sum of scores of all alternative
annotations to a value of 100. Hence, each score indicates the percentage of peak
intensity that is explained by the respective glycoform. Scores for alternative O-core
annotations in Fig. 2b were calculated likewise, using relative O-core abundances
derived from the mass spectrum in Fig. 2a.
Glycopeptide analysis by HPLC-MS/MS. HPLC-MS/MS analyses of Etanercept
digested with either trypsin or AspN were carried out on a Thermo ScientiﬁcTM
VanquishTM Horizon UHPLC system (Thermo Fisher Scientiﬁc, Germering,
Germany) coupled with the Thermo ScientiﬁcTM Orbitrap FusionTM TribridTM
mass spectrometer (Thermo Fisher Scientiﬁc, San Jose, CA, USA) equipped with an
HESI-II source. Five microliters of tryptic digest (1.0 mg mL−1) and 10 μL of AspN
digest (0.50 mg mL−1) were injected, respectively. Chromatographic separation was
achieved via a 150 × 2.1 mm Ascentis Express Peptide ES-C18 column (Supelco,
Bellefonte, PE, USA) with 2.7 μm particle size operated at 55 °C. A gradient from
5.0 to 40% mobile phase B over 90 min with a ﬂow rate of 200 μLmin−1 was
applied with mobile phases A: water with 0.05% TFA (LC-MS grade, Fluka Ana-
lytical) and B: acetonitrile (gradient grade for LC, Merck) with 0.05% TFA.
Mass spectrometric data were acquired using a data dependent Top5 method
comprising of a full scan followed by ﬁve MS/MS scans in each scan cycle. Full MS
scans were acquired in the Orbitrap mass analyzer with the mass range set to m/z
350–2000, a resolution setting of 60,000 at m/z 200 with an automatic gain control
(AGC) target value of 2e5 and a maximum injection time of 150 ms. HCD MS/MS
scans were acquired in the Orbitrap mass analyzer with a resolution setting of
15,000 at m/z 200, the precursor isolation window set to 3 Th, 30% normalized
collision energy, an AGC target of 5e4, a maximum injection time of 250 ms and a
ﬁxed ﬁrst mass of 120 Th. Data evaluation were performed with BioPharma
FinderTM 1.0 SP1 software (Thermo Fisher Scientiﬁc). The following parameters
were used: 200.0 S/N threshold, 5 ppm mass accuracy, 0.8 minimum conﬁdence,
speciﬁcity ‘high’ for the applied proteases, carbamidomethylation of the 29
cysteines as a ﬁxed modiﬁcation, and the built-in N-glycan repertoire for Chinese
hamster ovary cell lines as variable modiﬁcations. Lys-variants were determined
based on the tryptic peptides SLSLSPG and SLSLSPGK using a minimum
conﬁdence score setting of 0.0 in the BioPharma FinderTM software.
Code availability. MoFi software is freely available as source code from GitHub
(https://github.com/cdl-biosimilars/moﬁ) and as a frozen executable for Linux and
Windows (http://cdl-biosimilars.sbg.ac.at).
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Data availability. The following ﬁles used in this study are provided as ZIP archive
(Supplementary Data 1) and on ﬁgshare (https://doi.org/10.6084/m9.
ﬁgshare.6016106): raw spectra (in RAW and mzML format); MoFi parameter and
output ﬁles; processed results and the corresponding processing scripts; glyco-
peptide data. See the readme ﬁle for further details. The data that support the
ﬁndings of this study are available from the corresponding author upon request.
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